ARTICLE | Clinical News
Myozyme regulatory update
August 1, 2005 7:00 AM UTC
GENZ submitted a BLA to FDA for Myozyme to treat Pompe's disease. The company is seeking Priority Review. Myozyme has Orphan Drug designation in the U.S. and Europe, and also is under EMEA review (see...